



DAFTAR PUSTAKA

- Abry E, Thomassen, Salvesen, Torp SH. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. *Pathol Res Pract*. 2010; Acknowledgments 206(12):810-815
- Almefty Osama, De Monte F., McDermott M.W., Al-Mefty's Meningiomas. 2nd edition. 2011.
- Boulagnon-Rombi C, Fleury C, Fichel C, Lefour S, Marchal Bressenot A, Gauchotte G. Immunohistochemical Approach to the Differential Diagnosis of Meningiomas and Their Mimics. *J Neuropathol Exp Neurol*. 2017 Apr 1;76(4):289-298. doi: 10.1093/jnen/nlx008. PMID: 28340171.
- Choy, W.C. et al. (2011) "The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments," *Neurosurgical Focus* [Preprint]. doi:10.3171/2011.2.FOCUS1116.
- de Carvalho GTC, da Silva-Martins WC, de Magalhães KCSF, Nunes CB, Soares AN, Tafuri LSA, Simões RT. Recurrence/Regrowth in Grade I Meningioma: How to Predict? *Front Oncol*. 2020 Aug 4;10:1144. doi: 10.3389/fonc.2020.01144. PMID: 32903787; PMCID: PMC7438949.
- Ellis LM, Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer* 8:579–591, 2008
- Fatterpekar G. *The Teaching Files: Head and Neck Imaging, Expert Consult - Online and Print*. W B Saunders Co. (2010) ISBN:1416060596.
- Flynn JR, Wang L, Gillespie DL, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. *Cancer*. 2008;113(5):1032-1042
- H. Richard Winn, M. Youmans & Winn *Neurological Surgery*. 2017
- Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. *Neuro Oncol*. 2019 Jan 1;21(1):26-36. doi: 10.1093/neuonc/noy137. PMID: 30137421; PMCID: PMC6303427.
- Hou, J. et al. (2013) "Peritumoral brain edema in intracranial meningiomas: The emergence of vascular endothelial growth factor-directed therapy," *Neurosurgical Focus* [Preprint]. doi:10.3171/2013.8.FOCUS13301.



Iskandar, M. M., Aman, R. A., Tjahjadi, H., Safri, A. Y., & Aninditha, T. (2017). The identification of factors affecting intracranial meningioma recurrence two years postoperatively. *Journal of Physics: Conference Series*, 884(1), Article 012032. <https://doi.org/10.1088/1742-6596/884/1/012032>

Jensen R, Lee J. Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation. *Neurosurgery*. 2012;71:146–56.

Karsy M, Burnett B, Di Ieva A, Cusimano MD, Jensen RL. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome. *J Neurosurg*. 2018 Mar;128(3):657-666. doi: 10.3171/2016.10.JNS161825. Epub 2017 Mar 31. PMID: 28362240.

Kerbel RS: Tumor angiogenesis. *N Engl J Med* 358:2039– 2049, 2008

Korkolopoulou P, Patsouris E, Konstantinidou AE, et al. Hypoxia-inducible factor 1 alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. *Neuropathol Appl Neurobiol*. 2004;30(3):267-278

Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. *Neurosurgery*. 2000;46:938–48

Lee, S.H. et al. (2014) “Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas,” *APMIS* [Preprint]. doi:10.1111/apm.12079.

Shibuya, M. (2001) “VEGF and its receptors,” *Biotherapy* [Preprint]. doi:10.1007/978-1-4419-9148-51.

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol*. 2016;131:803–820.

Maiuri F, de Caro MB, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, et al. Recurrences of meningiomas: Predictive value of pathological features and hormonal and growth factors. *J Neurooncol*. 2007;82:63–8.

Marosi, C. et al. (2008) “Meningioma,” *Critical Reviews in Oncology/Hematology* [Preprint]. doi:10.1016/j.critrevonc.2008.01.010.

Mirna Marhami Iskandar; Tiara Aninditha, supervisor; Renindra Ananda Aman, supervisor; Hartono Tjahjadi, supervisor; Ahmad Yanuar Safri, supervisor; Teguh Asaad Suhatno Ranakusuma, examiner; Salim Harris, examiner; M. Kurniawan, examiner; Henry Riyanto Sofyan. Factors affecting recurrence risk in intracranial meningiomas two years post surgery
tim



March 2023.

Ostrom, Q.T.; Cioffi, G.; Gittleman, H.; Patil, N.; Waite, K.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. *Neuro Oncol.* 2019, 21, v1–v100.

Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M, et al: Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. *Neuropathol Appl Neurobiol* 30:118–125, 2004

Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. *Lancet Neurol.* 2006;5(12):1045-1054.

Simpson D. The recurrence of intracranial meningiomas after surgical treatment. *J Neurol Neurosurg Psychiatry* 1957; 20:22–39.

Takahashi, H. and Shibuya, M. (2005) “The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions,” *Clinical Science* [Preprint]. doi:10.1042/CS20040370.

Tao Y, Liang G, Li Z, Wang Y, Wu A, Wang H, Lu Y, Liu Z, Hu G. Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse. *Br J Neurosurg.* 2012 Oct;26(5):700-4. doi: 10.3109/02688697.2012.685780. Epub 2012 May 22. PMID: 22616825.

Winter, R.C., Antunes, A.C.M. and De Oliveira, F.H. (2020) “The relationship between vascular endothelial growth factor and histological grade in intracranial meningioma,” *Surgical Neurology International* [Preprint]. doi:10.25259/SNI_528_2020.

Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas. *Cancer.* 2000;89:1102–10.